Start the conversation
United Therapeutics Corp.'s (UTHR) second quarter earnings of $1.43 per share were well above the year-ago earnings of $1.19 and the Zacks Consensus Estimate of $1.12. Higher revenues led to the improvement in earnings. The company maintained its guidance for 2012. We believe the company is well-positioned to gain share in the pulmonary arterial hypertension (PAH) market.
Lead product Remodulin continues to look very strong in both the intravenous (IV) and subcutaneous (SC) forms. With the approval of Adcirca and Tyvaso, the company has a varied range of therapies available for the treatment of PAH. We believe the company's PAH product portfolio will drive strong top-and bottom-line growth.
We maintain our Outperform recommendation on United Therapeutics, which carries a Zacks #2 Rank (short-term Buy rating). We have raised our target price by $5 to $70 based on the strong second quarter results. Our new price target is based on 14.0x our 2012 EPS estimate.
UTD THERAPEUTIC (UTHR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Here Are 10 “One-Click” Ways to Earn 10% or Better on Your Money Every Quarter
Appreciation is great, but it’s possible to get even more out of the shares you own. A lot more: you can easily beat inflation and collect regular income to spare. There are no complicated trades to put on, no high-level options clearances necessary. In fact, you can do this with a couple of mouse clicks – passive income redefined. Click here for the report…